Please enter exact key words
Radiolabeled Anti-FZD10 Antibodies

for Cancer Therapy

Home / Available Projects / Radiolabeled Anti-FZD10 Antibodies
Drug Name GPCR-targeted Project 019

Frizzled homologue 10 (FZD10) is a member of the Frizzled family and acts as a receptor for Wnt proteins. FZD10 has shown to be upregulated in cancer types such as colorectal cancer, gastric cancer, and synovial sarcoma, but is not present in normal human organs.
A radiolabeled chimeric monoclonal antibody against FZD10 is being developed for the treatment of cancers in early preclinical studies.

Target Frizzled homologue 10 (FZD10)
Drug Modality Monoclonal antibody
Indication Cancers
Product Category Biologic
Mechanism of Action Wnt signaling pathway inhibitors
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.